Boomerang Medical, a clinical-stage company pioneering bioelectronic medicine for autoimmune diseases, has raised $20 million in Series B financing. The round was co-led by Arboretum Ventures and Hatteras Venture Partners, marking a strong endorsement of Boomerang’s mission to deliver non-pharmacologic therapies for chronic conditions affecting millions worldwide.

Founded and led by Heather Simonsen (CEO), Boomerang Medical is at the forefront of a new wave of medtech innovation - one that blends neuromodulation, immunology, and engineering to address some of the most difficult-to-treat diseases.

Tackling Autoimmune Diseases Through Bioelectronic Innovation

Autoimmune conditions such as Crohn’s disease, rheumatoid arthritis, and ulcerative colitis are often managed through pharmaceuticals that suppress the immune system. While effective for many, these treatments can bring serious side effects and don’t work for all patients.

Boomerang Medical is developing a novel bioelectronic platform that uses neuromodulation to recalibrate the body’s immune response. By targeting specific neural pathways, their technology aims to reduce inflammation without the systemic risks associated with drug therapies. The company’s approach is rooted in rigorous clinical science and has the potential to reshape how we view and treat autoimmune disorders at scale.

What’s striking about Boomerang’s trajectory isn’t just the science - it’s the strategy. Rather than spreading their resources across multiple therapeutic areas early, they’ve narrowed their focus to autoimmune disease, a domain where the unmet need is massive and patient demand for alternatives is urgent. This disciplined focus is what makes the company investable. And here’s a core lesson for founders: capital follows clarity, not possibility. Too many startups pitch the broadest vision possible, thinking it will excite investors. But in reality, it’s the startups that draw sharp lines around the first problem they will dominate that raise capital faster. By committing to one critical vertical before expanding outward, Boomerang signals to investors not just potential, but probability. That signal is what unlocks meaningful rounds like this Series B.

Investors Betting on the Future of Bioelectronic Medicine

Boomerang Medical’s Series B was co-led by Arboretum Ventures, a leading healthcare-focused venture firm with a track record of scaling medical technology companies, and Hatteras Venture Partners, known for backing breakthrough health innovations. Both firms bring not only capital but also deep operational and regulatory expertise to guide Boomerang through clinical validation and commercialization.

The syndicate also reflects a growing trend: top-tier healthcare VCs are moving decisively into bioelectronic medicine, seeing it as a category-defining force with parallels to biotech’s rise in the 1980s.

Leadership Built for Clinical and Commercial Success

CEO Heather Simonsen brings extensive experience in medical devices and scaling clinical-stage ventures. Under her leadership, Boomerang has built a multidisciplinary team spanning neuroscience, immunology, and regulatory affairs. This combination positions the company not just to advance trials but also to navigate the complex pathways required for FDA clearance and broad adoption.

Roadmap Ahead

With the fresh $20 million, Boomerang Medical plans to accelerate its ongoing clinical trials, expand research into new autoimmune indications, and continue building partnerships with leading medical centers. The funding will also support the company’s efforts to strengthen data generation, which is crucial for both regulatory approvals and eventual reimbursement discussions with payers.

Boomerang is entering a pivotal stage: one where clinical validation meets market readiness. If successful, the company could become a leader in the emerging bioelectronic medicine sector, carving out a new category of care that reduces reliance on drugs and reshapes treatment standards for autoimmune disease.

Why Boomerang Matters

Beyond the funding headlines, Boomerang Medical represents a paradigm shift in how healthcare innovators approach chronic disease. Instead of accepting the status quo of lifelong medication, the company is pioneering a future where electrical signals, rather than pharmaceuticals, hold the key to lasting relief.

Their success underscores a larger trend in healthcare innovation - one where precision, personalization, and non-drug solutions are no longer fringe but central to the industry’s evolution.